



**Comprehensive de-identified patient-level clinical EHR data representing standard of care in oncology treatment to power complex clinical and research questions**

**Longitudinal:**

- Patient Identification Period<sup>1</sup>: 5 years
- Historical Lookback: Full (provides information from the day of diagnosis)
- Prospective: 1 year

<sup>1</sup>Inclusion criteria = evidence of cancer diagnosis that is the focus of the Clinical Data View within the identification period and at least one in-person patient visit at the practice

**Training/Education Support**

- 10 hours allowance per month

**Standard Data Refresh Frequency<sup>2</sup>**

- Monthly

<sup>2</sup>Data Refresh will retain baseline data from the initial time period and then add new data as well as newly diagnosed patients during the license period

**License Rights to Publish**

- Included

**Clinical Data Views™ – Effectiveness & Outcomes**

Providing researchers with clinically rich treatment and outcomes oncology data to prove the real-world impact of therapeutic and medical products

**Clinical Data Views - Effectiveness & Outcomes** is a de-identified, longitudinal, patient-level oncology data product built to reflect standard of care based on NCCN guidelines in the community oncology setting. It is powered by structured clinical data in iKnowMed (single source EHR), which captures information on more than 2.4 million patients and spans more than 85 cancer types. With near real-time NCCN updates that reflect treatment changes as standard of care evolves, relevant patient cohorts can be constructed and examined swiftly in the evolving treatment landscape. This data can be integrated with other data sources, such as in-office dispensing and claims.

Optimized to support primarily commercial RWD analyses and decisions across the product life cycle, this standardized comprehensive data product is clinician-designed to the standard of care for the tumor type. It includes structured fields containing patient-level performance status, stage at diagnosis, actionable biomarker data, labs, mortality status, treatment regimen and therapy sequencing. Mortality data enhances completeness and will be validated with third party data coming later this year. Tumor specific clinical data elements will help identify critical subpopulations.

**Biomarker Enhancements:** Effectiveness & Outcomes includes extensive biomarker data from the EHR and biomarker results from select NGS labs covering 2016-2022 and partial data for 2023.

**Designed to power:**

- |  |                                     |
|--|-------------------------------------|
| • Clinical Trial Feasibility             | Line of Therapy Detailed Analysis   |
| • Clinico-Genomic Profiling              | Market Share Analysis               |
| • Competitive Landscape Characterization | Market Sizing                       |
| • Detailed Disease Diagnosis             | Outcomes and Survivorship           |
| • Drug Class Competitive Dynamics        | Patient Cohort Monitoring           |
| • Drug Sequencing                        | Patient Treatment Journey           |
| • Drug Utilization                       | Synthetic Control Trial Feasibility |
| • End-to-End Patient Journey             | Therapeutic Effectiveness           |
| • Forecasting                            | Treatment Patterns                  |
| • Histology                              |                                     |

\*Data dictionary available upon request

**Ontada by the Numbers**

**25+**

Tumor types with mutation level data

**350K**

Patients with linked biomarkers

**40+**

Actionable biomarkers



**For More Information:**  
[Visit.ontada.com](http://Visit.ontada.com)